Age-related macular degeneration: suitability of optogenetic therapy for geographic atrophy
Age-related macular degeneration (AMD) is a growing public health concern given the aging population and it is the leading cause of blindness in developed countries, affecting individuals over the age of 55 years. AMD affects the retinal pigment epithelium (RPE) and Bruch’s membrane in the macula, l...
Main Authors: | Borchert, GA, Shamsnajafabadi, H, Ng, BWJ, Xue, K, De Silva, SR, Downes, SM, MacLaren, RE, Cehajic-Kapetanovic, J |
---|---|
Format: | Journal article |
Language: | English |
Published: |
Frontiers Media
2024
|
Similar Items
-
The Role of Inflammation in Age-Related Macular Degeneration—Therapeutic Landscapes in Geographic Atrophy
by: Grace A. Borchert, et al.
Published: (2023-08-01) -
Optogenetic Gene Therapy for the Degenerate Retina: Recent Advances
by: Michelle E. McClements, et al.
Published: (2020-11-01) -
Real-world six-month outcomes in patients switched to faricimab following partial response to anti-VEGF therapy for neovascular age-related macular degeneration and diabetic macular oedema
by: Borchert, GA, et al.
Published: (2024) -
Current and Future Landscape in Genetic Therapies for Leber Hereditary Optic Neuropathy
by: Hoda Shamsnajafabadi, et al.
Published: (2023-08-01) -
Gene therapy for age-related macular degeneration
by: MacLaren, RE
Published: (2015)